Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers

Aims: The LEADER trial demonstrated that the glucagon-like peptide-1 receptor agonist (GLP1-RA) liraglutide reduces kidney and cardiovascular (CV) risk in patients with type 2 diabetes. We previously developed a Parameter Response Efficacy (PRE) score that translates multiple short-term risk marker...

Descripción completa

Detalles Bibliográficos
Autores principales: Tye, Sok Cin, de Vries, Sieta T., Mann, Johannes F. E., Schechter, Meir, Mosenzon, Ofri, Denig, Petra, Heerspink, Hiddo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044907/
https://www.ncbi.nlm.nih.gov/pubmed/35496307
http://dx.doi.org/10.3389/fphar.2022.786767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044907/
https://www.ncbi.nlm.nih.gov/pubmed/35496307
http://dx.doi.org/10.3389/fphar.2022.786767

Ejemplares similares